Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Search results for

There are 21,958 results that match your search.21,958 results
  • rasser-nov02.jpg
    European and US patent protection compared
    As European politicians consider fundamental reforms to patent protection, one of the key questions they have to address is how to make the system more efficient. In particular, some critics believe Europe needs to look to the US model to improve its effectiveness. In a special MIP debate, Koos Rasser argues that the European patent system as it exists today is substantially inferior to that of the US, while Simon Mounteney says that, though not perfect, Europe offers many benefits to applicants
    Managing IP Correspondent, November 01 2002
  • Building a world-class IP system
    Rosella L Fernandez, assistant director, and Emma C Francisco, director general, Philippines Bureau of Patents
    Managing IP Correspondent, November 01 2002
  • carmichael-nov02.jpg
    JPO search/examination reports and patents recognized
    Singapore's patent rules have been amended this year to recognize search and examination reports and patents issued by the Japanese Patent Office (JPO) in the grant process of Singapore patents. Singapore patent applications with a priority filing date on or after August 15 2002, may rely on JPO search and examination reports and granted patents in place of local search and examination.
    Managing IP Correspondent, November 01 2002
  • bae-nov02.jpg
    What estoppel means in Korea after Festo
    In July 2000, the Korean Supreme Court handed down its first decision specifically stating the requirements for the doctrine of equivalents. Afterwards, many other relevant precedent cases have also been decided in a rather short period of time.
    Managing IP Correspondent, November 01 2002
  • New trade mark law goes nowhere
    It is no great news to report that bureaucratic delays continue to dog the new Trademarks Act passed by the Indian parliament way back in 1999 with much TRIPs Agreement-compliant hype and fanfare. The latest to join the game of hurdles is a writ filed before the High Court of Delhi, challenging certain aspects of the new law.
    Managing IP Correspondent, November 01 2002
  • BMS faces pressure in Thailand
    An action to revoke its patent on the drug Videx EC threatens to limit further Bristol-Myers Squibb's (BMS) rights to sell Aids medicines in Thailand. Three Aids patients and the Foundation for Consumers, a local group, claim that the US pharmaceutical company did not invent the drug and so should not be allowed to own the rights to it in Thailand. According to the plaintiffs, the drug is a product of collaboration between BMS and the US National Institutes of Health (NIH).
    Managing IP Correspondent, November 01 2002
  • nohlen-nov02.jpg
    Less is more for equivalents
    In a series of four decisions rendered recently by the German Federal Supreme Court (BGH), the Court considered the extent to which the doctrine of equivalents applies to patent claims reciting numerical ranges: BGH GRUR 2002, 515 - Schneidmesser I (in English, Cutting Knife I); 519 - Schneidmesser II; 523 - Custodiol I; 527 - Custodiol II.
    Managing IP Correspondent, November 01 2002
  • prilosec-nov02.jpg
    AstraZeneca's purple pill under threat
    Pharma company AstraZeneca has stopped three generics from launching rival versions of its multi-billion dollar drug Prilosec in the US. But a fourth generic company is free to manufacture its own version of the drug.
    Managing IP Correspondent, November 01 2002
  • thomas-nov02.jpg
    An inexhaustible question
    One might have thought that the question of the exhaustion of trade marks in the European Economic Area (EEA) had been resolved, or at least stabilized, to a certain extent.
    Managing IP Correspondent, November 01 2002
  • bushgw-nov02.jpg
    Bush backs generics
    George W Bush The US government has moved to make generic drugs more widely available. In an announcement on October 22, President George W Bush said he would adopt key recommendations made by the FTC in its report into competition in the industry.
    Managing IP Correspondent, November 01 2002
Previous
1
...
2074
2075
2076
2077
2078
...
2195
Next